press center press release

DelMar Pharmaceuticals Inc. (Nasdaq: DMPI) to Ring The Nasdaq Stock Market Opening Bell

Published

ADVISORY, July 13, 2016 (GLOBE NEWSWIRE) --

What: 

DelMar Pharmaceuticals Inc. (Nasdaq:DMPI), a company focused on developing and commercializing proven cancer therapies in new orphan drug indications will visit the Nasdaq MarketSite in Times Square in celebration of its recent uplisting. 

In honor of the occasion, Jeffrey Bacha, Chairman and CEO, will ring the Opening Bell. 

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Thursday, July 14, 2016  – 9:15 a.m. to 9:30 a.m. ET

DelMar Pharmaceuticals Media Contact:

Eric Fischgrund

646-699-1414

eric@fischtankpr.com

Nasdaq MarketSite:

Emily Pan

(646) 441-5120

emily.pan@nasdaq.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:

http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:

http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:

http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:

http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:

http://nasdaq.tumblr.com/

Webcast:

A live stream of the Nasdaq Opening Bell will be available at:

https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.

About DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerant to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For further information, please visit www.delmarpharma.com; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989. Connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.3 trillion and nearly 17,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-

In This Story

NDAQ

Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more